Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma

Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma

Authors

  • Marek Pasek Department of Dermatology and Venereology, Third School of Medicine, Charles University https://orcid.org/0009-0000-0875-8332
  • Eva Sticová Department of Pathology, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic https://orcid.org/0000-0003-2486-6266
  • Emanuel Marques Department of Dermatology and Venereology, St. Joseph Local Health Unit, Lisbon, Portugal and Department of Dermatology and Venereology, NOVA Medical School, NOVA University Lisbon, Portugal https://orcid.org/0000-0003-1451-6115
  • Vojtěch Tretera Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic https://orcid.org/0009-0002-5557-6026
  • Petr Arenberger Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic https://orcid.org/0000-0002-4800-5877
  • Monika Arenbergerová Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic https://orcid.org/0000-0002-7919-9619

Keywords:

melanoma, anti-PD-1, anti-LAG-3, adverse events

References

Tawbi HA, Schadendorf D, Lipson EJ, et al. RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386(1):24-34. DOI: 10.1056/NEJMoa2109970. PMID: 34986285. PMCID: PMC9844513.

Seth R, Agarwala SS, Messersmith H, et al. Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023;41(30):4794-20. DOI: 10.1200/JCO.23.01136. PMID: 37579248.

Litaiem N, Mansour Y, Jones M, et al. Dermoscopic signs of lichen planus. BMJ Case Rep. 2016;2016:bcr2015213923. DOI: 10.1136/bcr-2015-213923. PMID: 26759406. PMCID: PMC4716428.

National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), ver. 5.0. 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf Accessed April 3, 2023.

Nikolaou V, Tsimpidakis A, Stratigos A. Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma. Cancers (Basel). 2023;15(7):2084. DOI: 10.3390/cancers15072084. PMID: 37046745. PMCID: PMC10093334.

Downloads

Published

2025-01-29

How to Cite

1.
Pasek M, Sticová E, Marques E, Tretera V, Arenberger P, Arenbergerová M. Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma. Dermatol Pract Concept. 2025;15(1):4967. doi:10.5826/dpc.1501a4967

Share